Loading...
 
Translate Register Log In Login with facebookLogin and Register

Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018

High-dose ω-3 Fatty Acid Plus Vitamin D3 Supplementation Affects Clinical Symptoms and Metabolic Status of Patients with Multiple Sclerosis: A Randomized Controlled Clinical Trial

The Journal of Nutrition, nxy116, https://doi.org/10.1093/jn/nxy116
Ebrahim Kouchaki Maryam Afarini Javad Abolhassani Naghmeh Mirhosseini Fereshteh Bahmani Seyed Ali Masoud Zatollah Asemi

VitaminDWiki

Short 12 week trial using 50,000 IU of vitamin D bi-weekly
In conjuction with 2 × 1000 mg/d ω-3 fatty acid (we assume the Omega-3 was daily)
This was a radomized controlled trial of Vit D + Omega-3 vs placebo
Nice to see trials like this starting to use more than monotherapy
   ( e.g. just Vitamin D OR just Omega-3)
Would expect even more benefit if trial had lasted longer - say 6 months
Would expect even more benefit if trial had used more vitamin D
Note: MS has been cured in > 2,000 people with daily doses ranging from 20,000 - 140,000 IU
   = approximately 140,000 - 1,960,000 IU if given bi-weekly
   = 3X - 39X more Vitamin D than used in this study


UV and Sunshine reduces MS risk

Omega-3 helps Vitamin D

High Dose Vitamin D and cofactors

 Download the PDF from VitaminDWiki

Background: Combined omega-3 fatty acid and vitamin D supplementation may improve multiple sclerosis (MS) by correcting metabolic abnormalities and attenuating oxidative stress and inflammation.

Objective: This study aimed to determine the effects of ω-3 fatty acid and vitamin D cosupplementation on the disability score and metabolic status of patients with MS.

Methods
This was a randomized, placebo-controlled clinical trial with Expanded Disability Status Scale (EDSS) score and inflammation as primary outcomes and oxidative stress biomarkers and metabolic profile as secondary outcomes. Patients, aged 18–55 y, were matched for disease EDSS scores, gender, medications, BMI, and age (n = 53) and randomly received a combined 2 × 1000 mg/d ω-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement or placebo for 12 wk. The placebos were matched in colour, shape, size, packaging, smell, and taste with supplements. Fasting blood samples were collected at baseline and end of intervention to measure different outcomes. Multiple linear regression models were used to assess treatment effects on outcomes adjusting for confounding variables.

Results
Patients taking ω-3 fatty acid plus vitamin D supplements showed a significant improvement in

  • EDSS (β −0.18; 95% CI: −0.33, −0.04; P = 0.01), compared with placebo.
  • Serum high-sensitivity C-reactive protein (β −1.70 mg/L; 95% CI: −2.49, −0.90 mg/L; P < 0.001),
  • plasma total antioxidant capacity (β +55.4 mmol/L; 95% CI: 9.2, 101.6 mmol/L; P = 0.02),
  • total glutathione (β +51.14 µmol/L; 95% CI: 14.42, 87.87 µmol/L; P = 0.007), and
  • malondialdehyde concentrations (β −0.86 µmol/L; 95% CI: −1.10, −0.63 µmol/L; P < 0.001)

were significantly improved in the supplemented group compared with the placebo group.
In addition, ω-3 fatty acid and vitamin D cosupplementation resulted in a significant reduction in

  • serum insulin,
  • insulin resistance, and
  • total/HDL-cholesterol,

and a significant increase in

  • insulin sensitivity and
  • serum HDL-cholesterol concentrations.

Conclusion
Overall, taking ω-3 fatty acid and vitamin D supplements for 12 wk by patients with MS had beneficial effects on EDSS and metabolic status.

This trial was registered at the Iranian website (www.irct.ir) for registration of clinical trials as IRCT2017090133941N20.

Created by admin. Last Modification: Saturday December 7, 2019 13:16:46 GMT-0000 by admin. (Version 9)

Attached files

ID Name Comment Uploaded Size Downloads
11940 MS Vit D, Omega-3.pdf PDF 2019 admin 11 May, 2019 11:25 194.25 Kb 59
See any problem with this page? Report it (FINALLY WORKS)